{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:02:39Z","timestamp":1756425759005,"version":"3.44.0"},"reference-count":17,"publisher":"BMJ","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:p>In 2009, nearly 1.2 million prescriptions for topical antibacterials were dispensed for acne in primary care in England, at a cost of nearly \u00a315million (around 80% of expenditure on topical preparations for acne).1 Here we consider the place of such therapy, including the risk of bacterial resistance.<\/jats:p>","DOI":"10.1136\/dtb.2010.12.0062","type":"journal-article","created":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T04:49:51Z","timestamp":1291178991000},"page":"141-144","source":"Crossref","is-referenced-by-count":0,"title":["What role for topical antibacterials in acne?"],"prefix":"10.1136","volume":"48","member":"239","published-online":{"date-parts":[[2010,12,1]]},"reference":[{"key":"2025082723392743000_48.12.141.1","unstructured":"The NHS Information Centre, 2010. Prescription cost analysis: England 2009 [online]. Available: http:\/\/www.ic.nhs.uk\/webfiles\/publications\/prescostanalysis2009\/PCA_2009.pdf [Accessed 18 November 2010]."},{"key":"2025082723392743000_48.12.141.2","doi-asserted-by":"crossref","unstructured":"Layton A . Disorders of the sebaceous glands. In: Burns DA . (Eds). Rook's Textbook of Dermatology. Eighth edition. London: Blackwell Publishing, 2010.","DOI":"10.1002\/9781444317633.ch42"},{"key":"2025082723392743000_48.12.141.3","unstructured":"Garner SE . Acne vulgaris. In: Williams H (Ed). Evidence Based Dermatology. London: BMJ, 2003."},{"key":"2025082723392743000_48.12.141.4","unstructured":"Schofield JK . Skin conditions in the UK: a health care needs assessment. First edition. Nottingham: Centre of Evidence Based Dermatology, 2009."},{"key":"2025082723392743000_48.12.141.5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04346.x"},{"key":"2025082723392743000_48.12.141.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.08.048"},{"key":"2025082723392743000_48.12.141.7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1586\/17469872.3.5.595","article-title":"Current measures for the evaluation of acne severity","volume":"3","author":"Tan","year":"2008","journal-title":"Expert Rev Dermatol"},{"key":"2025082723392743000_48.12.141.8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaad.2009.01.019","article-title":"New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne Group","volume":"60","author":"Thiboutot","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2025082723392743000_48.12.141.9","unstructured":"Clinical Knowledge Summaries. Acne vulgaris [online]. Available: http:\/\/www.cks.nhs.uk\/acne_vulgaris [Accessed 18 November 2010]."},{"key":"2025082723392743000_48.12.141.10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00128072-200305050-00003","article-title":"Guidelines for the management of Acne vulgaris in adolescents","volume":"5","author":"Goulden","year":"2003","journal-title":"Paediatr Drugs"},{"key":"2025082723392743000_48.12.141.11","unstructured":"Joint Formulary Committee. British National Formulary. Edition 60. London: BMJ Group and RPS Publishing, September 2010."},{"key":"2025082723392743000_48.12.141.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704173361607"},{"key":"2025082723392743000_48.12.141.13","unstructured":"Lehmann HP . Management of Acne. Agency for Healthcare Research and Quality \u00e2\u0080\u0093 Evidence reports\/technology assessments no.17 [online]. Available: www.ncbi.nlm.nih.gov\/bookshelf\/br.fcgi?book=erta17 [Accessed 18 November 2010]."},{"key":"2025082723392743000_48.12.141.14","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta9010","article-title":"Randomised controlled multiple treatment comparison to provide a cost effectiveness rationale for the selection of antimicrobial therapy in acne","volume":"9","author":"Ozolins","year":"2005","journal-title":"Health Technology Assessment"},{"key":"2025082723392743000_48.12.141.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70177-4"},{"key":"2025082723392743000_48.12.141.16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/120347540100500109","article-title":"The efficacy and safety of a combination benzoyl peroxide\/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide\/erythromycin combination product","volume":"5","author":"Leyden","year":"2001","journal-title":"J Cutan Med Surg"},{"key":"2025082723392743000_48.12.141.17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2133.2005.06614.x","article-title":"Treatment of acne with topical antibiotics: lessons from clinical studies","volume":"153","author":"Simonart","year":"2005","journal-title":"Br J Dermatol"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2010.12.0062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:39:34Z","timestamp":1756363174000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2010.12.0062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2010,12,1]]},"published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1136\/dtb.2010.12.0062"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2010.12.0062","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}